Annual Reports

Annual Report 2018-19

  Download

Annual Report 2017-18

  Download

Annual Report 2016-17

  Download

Annual Report - FY15-16

  Download

Annual Report - FY14-15

  Download

Annual Report - FY13-14

  Download

Annual Report - FY12-13

  Download

Annual Report - FY11-12

  Download

Annual Report - FY10-11

  Download

Annual Report - FY09-10

  Download

Annual Report - FY08-09

  Download

Annual Report - FY07-08

  Download

Annual Report - FY06-07

  Download

Annual Report - FY05-06

  Download

Analyst Coverage

Research Firms Analyst E-mail id
Anand Rathi Rashmi Sancheti rashmisancheti@rathi.com
Bonanza Alka Katiyar alka.katiyar@bonanzaonline.com
BP Equities Nikhil Shetty nikhilshetty@bpwealth.com
Centrum Ranjit Kapadia ranjit.kapadia@centrum.co.in
Dalal & Broacha Charulata Gaidhani charulata.gaidhani@dalal-broacha.com
Emkay Jatin Kotian jatin.kotian@emkayglobal.com
HDFC Securities . Amey Chalke Amey.Chalke@hdfcsec.com
IIFL Bhavesh Gandhi bhaveshg@indiainfoline.com
KR Chowksy Hemanshu Srivastava hemanshu.srivastava@krchoksey.com
Motilal Oswal Kumar Saurabh kumar.saurabh@motilaloswal.com
Motilal Oswal Jehan Bhadha jehan.bhadha@motilaloswal.com
Nirmal Bang Runjhun Jain runjhun.jain@nirmalbang.com
PCS Securities C.Srihari balaprabhala@pcssecurities.co.in
Spark Capital Harith Ahamed harith@sparkcapital.in
Systematix Ranvir Singh ranvirsingh@systematixshares.com

Annual Accounts of Subsidiaries


Corporate Governance

Code of Conduct

Granules India Limited (Granules) ensures adherence and enforcement of the principles of corporate governance with a focus on transparency, professionalism, fairness and accountability. The Company believes that corporate governance has a role to ensure that the Directors of the Company are subject to their duties, obligations, accountability and responsibilities to act in the best interest of the Company and to remain accountable to shareholders and other beneficiaries for their corporate actions. The Company also believes that an active, well-informed and independent Board is necessary to ensure the highest standard of corporate governance. At Granules, the Board of Directors is at the core of corporate governance and oversees how the management serves and protects the interest of the stakeholders. The Board of Granules is responsible for and committed to the sound principles of the Company’s corporate governance. Our corporate governance framework ensures that we make timely disclosures and share accurate information regarding our financials and performance, as well as the leadership and governance of the Company. The Company acknowledges the individual and collective responsibilities to manage the business activities with integrity.


Committees

The Board Committees play a crucial role in the Company’s governance structure, and have been constituted to deal with specific areas / activities, which concern the Company and need a closer review. The Board Committees are set up under the formal approval of the Board to carry out clearly defined roles, which are considered to be performed by the Board members, as a part of good governance practice. The Board supervises the execution of its responsibilities by the committees and is responsible for their action. The minutes of the meetings of the committees are placed before the Board for review. The Board has currently established the following

statutory and non-statutory committees:


Audit Committee

The Audit Committee’s primary objective is to monitor and provide effective supervision of the management’s financial reporting process to ensure accurate, timely and proper disclosures and transparency, integrity and quality of financial reporting. The Committee oversees the work carried out by management, statutory auditors and internal auditors, in relation to the financial reporting process and the safeguards employed by them. The Company has qualified andindependent Audit Committee.

The Committee comprises four members, with a majority being Independent Directors. The composition, procedures, powers and role of the Committee comply with the requirements of Clause 49 of the listing agreement and Companies Act, 2013. The terms of reference of the Audit Committee includes:

  1. Overview of the Company’s financial reporting processand disclosure of its financial information to ensure thatthe financial statements reflect a true and fair positionand that sufficient and credible information is disclosed.
  2. Recommending the appointment and removal ofstatutory auditors, internal auditors and cost auditors,fixation of their audit fee and approval for payment forany other services.
  3. Reviewing financial statements and draft audit report,including quarterly / half-yearly financial information.
  4. Reviewing with the management the annual financialstatements before submission to the Board, focusingprimarily on:
    - The changes in accounting policies and practices.
    - Major accounting entries based on exercise ofjudgment by the management.
    - Qualifications in draft audit report.
    - Significant adjustment arising out of audit.
    - The going concern assumption.
    - Compliance with the accounting standards, stockexchange and legal requirements concerning financialstatements.
    - Review and approval of related party transactions.
  5. Reviewing, with the management, external and internalauditors, the adequacy and compliance of internalcontrol systems.
  6. Reviewing the adequacy of internal audit functions
  7. Discussion with the internal auditors on any significantfindings and follow up thereon.
  8. Reviewing the Company’s financial and risk managementpolicy.
  9. Any other function, as delegated by the Board from timeto time.

Nomination & Remuneration Committee

The Nomination & Remuneration Committee deals with allelements of remuneration package, stock options, servicecontracts and other terms and conditions of the service of the executive directors, directors’ / promoters’ relatives and the senior management. The remuneration policy is directed toward rewarding performance, based on review of achievements on a periodical basis. The remuneration policy is in consonance with the existing industry practice. The Company’s remuneration policy is primarily based on its performance and the potential, experience and performance of individual personnel and external environment.


Share Transfer and Stakeholders Relationship Committee

The Committee was constituted to specifically look into the matters of investors’ grievances, such as transfer, transmission, split and consolidation of investors’ holding, replacement of lost / mutilated / stolen share certificates and dematerialization of shares, non-receipt of dividend / notices / annual reports and change of addresses, among others. The Committee’s primary objective is to strengthen investor relations. It also evaluates the performance and service standards of the Registrar and Share Transfer Agent of the Company, and provides continuous guidance to improve the service levels for the investors.


Business Review Committee

The Board constituted a Business Review Committee to advice on matters related to the management / operations of the Company.


Corporate Social Responsibility (CSR) Committee

The CSR Committee’s main responsibility is to assist the Board in discharging its social responsibilities by way of formulating and monitoring the implementation of the framework of ‘corporate social responsibility policy’. The Committee’s constitution and terms of reference meet with the requirements of the Companies Act, 2013.


The Company Secretary shall act as the Secretary of the Committee. The Committee’s purpose is to formulate and monitor the Company’s CSR policy. The CSR Committee has adopted a policy that intends to:


   - Strive for economic development that positively impactsthe society at large with minimal resource footprints.
   - Be responsible for the Company’s actions and encourage apositive impact through its activities toward the environment,communities and stakeholders.


The Committee will be overseeing the activities / functioning relating to identifying the areas of CSR activities, programs, execution of initiatives, reporting the progress and making appropriate disclosures as per the policy.


Risk Management Committee

The Risk Management Committee (RM Committee) was constituted by the Board on October 30, 2014, adhering to the requirements of the Companies Act, 2013 and Clause 49 of the Listing Agreement. The Committee’s prime responsibility is to implement and monitor the Company’srisk management plan and policy.


The Committee’s Role and Responsibilities include:

   - Framing of Risk Management Plan and Policy
   - Overseeing implementation of Risk Management Planand Policy
   - Monitoring of Risk Management Plan and Policy
   - Verifying the process of Risk Management
   - Validating the procedure for Risk Minimisation
   - Periodically reviewing and evaluating the RiskManagement Policy and practices with respect to riskassessment and risk management processes
   - Continually obtaining reasonable assurance frommanagement that all known and emerging risks havebeen identified and mitigated or managed
   - Performing such other functions as may be necessary orappropriate for the performance of its oversight function


Board of Directors

Name of the Director Category
Mr. C. Krishna Prasad Chairman & Managing Director
Mr. L. S. Sarma Independent Director
Mr. A. P. Kurian Independent Director
Mr. C. Parthasarathy Independent Director
Dr. Krishna Murthy Ella Independent Director
Mr. Arun Rao Akinepally Independent Director
Mr.Harsha Chigurupati Non-Executive, Non-Independent Director
Mrs. Uma Devi Chigurupati Executive Director
Mr. K. B. Sankar Rao Non-Executive ,Non-Independent Director

Earnings Call Transcripts

First Quarter Second Quarter Third Quarter Fourth Quarter
FY20 Download Download
FY19 Download Download Download Download
FY18 Download Download Download Download

Revenue Break-up

Break-up of Consolidated Revenue as per Business Segment

(Rs in Mn.)



Break-up of Consolidated Revenue as per Molecule

(Rs in Mn.)



Break-up of Consolidated Revenue as per Geography

(Rs in Mn.)

Financial Highlights

REVENUE

(Rs in Mn.)

EBITDA

(Rs in Mn.)

EBITDA Margin (%)

(In %)

PAT

(Rs in Mn.)

PAT Margin (%)

(In %)

NETWORTH

(Rs in Mn.)

GROSS BLOCK

(Rs in Mn.)

  
Particulars FY'18 FY'17 FY'16
Revenue 16,918 14,353 13,829
EBITDA 2,893 3,088 2,815
EBITDA Margin(%) 17.1% 21.5% 20.4%
PAT 1,326 1,645 1,230
PAT Margin (%) 7.8% 11.5% 11.5%
Networth 13,042 9.036 6,616
Gross Block 11,996 9,837 8,230

Investor FAQ

Granules India Limited is a vertically integrated Indian pharmaceutical company, based in Hyderabad, India. We manufacture Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs). As Granules stands today, we are organized based on three segments; the Core business which comprises our 'core molecules- Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol; the New API business that focuses on manufacturing APIs with a focus on vertical integration and the CRAMS segment, which focuses on contract research and manufacturing.

Granules was incorporated in 1984.

Granules went public by listing its shares in 1995.

Granules is traded on the Bombay Stock Exchange under the code 532482 and National Stock Exchange under the symbol GRANULES.

Please visit Investor Section of the Granules' website to download the latest annual report.

The financial year ends on March 31.

Karvy Computer share Private Limited
Karvy Selenium Tower B, 6th Floor
Plot 31-32, Gachibowli, Financial District.
Nanakramguda, Hyderabad 500 008

Tel: +91-40-67161500

Toll Free No.: 1-800-3454-001;

Fax: +91-40-23001153

Investor Grievance ID: einward.ris@karvy.com

Website: www.karvycomputershare.com

Investor Relation Contact

For Institutional Investors & Financial Analysts

Mr.Saiprasad Madishetti
Granules India Limited
2nd Floor, 3rd Block, My Home Hub
Madhapur, Hyderabad (TS) – 500081
Tel: +91 40 30660000,
Fax: +91 40 23115145,
saiprasad.madishetti@granulesindia.com
Richa10.Singh@in.ey.com

For Retail Investors and Grievance

Ms.Chaitanya Tummala
Company Secretary,Compliance Officer and Nodal Officer
Granules India Limited
2nd Floor, 3rd Block, My Home Hub
Madhapur, Hyderabad (TS) – 500081
Tel: +91 40 30660000,
Fax: +91 40 23115145,
chaitanya.tummala@granulesindia.com
Write to us at investorrelations@granulesindia.com

Registrar and Transfer Agent

M/s. Karvy Fintech Private Limited
Karvy Selenium; Tower B,
Plot 31-32, Gachibowli, Financial District.
Hyderabad (TS) 500 032
Tel: +91-40-67161500,
Toll Free No.: 1-800-3454-001
Fax: +91-40-23001153,
Investor Grievance ID: einward.ris@karvy.com
Website: www.karvyfintech.com

Other Information

Other Information Downloads
Instructions for voting on Postal Ballot Resolution Download
E-Voting Instructions for 28th AGM Download
Appointment of Independent Directors - Mr. Arun Sawhney Download
Appointment of Independent Directors -Mrs. Jyothi Prasad Download
Appointment of Independent Directors - Mr. Robert George Cunard Download
Appointment of Independent Directors - Mr. C. Parthasarathy Download
Appointment of Independent Directors - Mr. A. Arun Rao Download
Committees of the Board Download
Code of practices and procedures for fair disclosure Download
Granules Whistle Blower Policy Download
Employee Details under Sec 197(12) of the Act. Download
E-Voting Instructions for 27th AGM Download
Transfer of Physical Shares in Demat Mode only Download
Performance Evaluation and Remuneration Policy Download
Special Purpose consolidated financials Download
E-voting instructions for 26th AGM Download
Familarisation Program for Independent Directors Download
Granules Dividend Distribution Policy Download
Remote e-Voting Instructions -25th AGM Download
25th AGM Notice-11.08.2016 Download
EGM voting results Download
24th AGM Voting Results Download
EGM – Remote e-voting Instructions Download
EGM Notice Download
Remote E-Voting Instructions-24th AGM Download
Granules Code of Conduct for Prevention of Insider Trading Download
e-voting instructions for EGM Download
EGM Notice Download
BSE Approval -Part B reg. Scheme of Amalgamation Download
High Court Order of Amalgamation Download
Oral order of Amalgamation Download
Granule's Related Party Transactions Policy Download
Granule's Policy on Material Subsidiaries Download
Outcome of 23rd AGM of Granules India Limited Download
Granules CSR Policy Download
NSE Observation Letter Download
BSE Observation Letter Download
Reply to Bombay Stock Exchange Download
Clause 24(F) documents Complaint Report Download
Scheme of Arrangement & Clause 24(f) documents Download

Presentations

Corporate Presentation
Corporate Brochure

Press Release

Press Release Date Download
Granules India’s Q2FY20 Adjusted Net Profit up 103% 22-10-2019 Download
Granules India Limited to divest its stake in its Joint Venture located in China 14-10-2019 Download
Granules India Limited to divest its stake in its Joint Venture located in India 29-08-2019 Download
Granules India’s Net Profit for first quarter of Financial Year 2020 increases by 61% 30-07-2019 Download
Granules India’s Total Income of FY’19 increases by 35% to INR 2,306 Cr. with Net Profit growth by 78% to INR 236 Crs. 09-05-2019 Download
ANDA approval for Acetaminophen 650 mg, Extended Release Tablets. 18-04-2019 Download
Promoters Block deal. 08-03-2019 Download
Granules India’s Net Profit grew by 72% to INR 60 Cr. 29-01-2019 Download
Granules India’s Net Profit grew by 49% to INR 60 Cr. 29-10-2018 Download
Granules India’s Total Income increases by 21% to INR 468 Cr. 23-07-2018 Download
Granules Pharmaceuticals, Inc. launched the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg 30.05.2018 Download
Granules India’s Total Income increases by 18% to INR 1,703 Cr 24-05-2018 Download
Granules Pharmaceuticals, Inc. received US FDA approval for generic Methylergonovine tablets 17-05-2018 Download
Granules India’s Revenue from operation increases by 14% to INR 411 Cr. 08-02-2018 Download
Granules India’s Revenue from operation increases by 8% to INR 393 Cr. 09-11-2017 Download
Granules India’s Revenue increases by 10% to Rs. 386 Cr. 16-08-2017 Download
Granules India’s Revenue increases 4% to Rs. 1,435 Cr.; Net Profit surges 34% to Rs. 165 Cr. 11-05-2017 Download
Granules India’s Net Profit rises by 34% to Rs. 39 Cr. 28-01-2017 Download
Granules India’s clarification on market rumours brought to our notice by few shareholders 06-09-2016 Download
Granules Pharmaceuticals, Inc., wholly owned subsidiary of Granules India Ltd entered into an agreement with USpharma to acquire its stake 14-07-2016 Download
Granules Pharmaceuticals, Inc., wholly owned subsidiary of Granules India Ltd entered into an agreement with USpharma Windlas, LLC for product in-licensing 09-06-2016 Download
Granules India’s Jeedimetla plant received Establishment Inspection Report (EIR) from the US FDA 30-05-2016 Download
Granules India’s Revenue increases 11% to Rs. 1,431 Cr.; Net Profit surges 30% to Rs. 118 Cr. 28-04-2016 Download
Granules India’s Revenue increases 8% to Rs. 345 Cr.; Net Profit surges 15% to Rs. 27 Cr 28-01-2016 Download
Granules USA entered into an agreement with Par Pharmaceutical Inc. to market generic version of omeprazole and sodium bicarbonate 21-01-2016 Download
Granules India’s two facilities located in Vizag and Jeedimetla completed U.S. FDA inspection 21-12-2015 Download
Granules India’s Revenue increases 19% to Rs. 366 Cr.; Net Profit surges 40% to Rs. 31 Cr. 31-10-2015 Download
Granules India receives US FDA approval for Ibuprofen Tablets 29-09-2015 Download
Granules India's Revenue increases 11% to Rs. 346 Cr.; Net Profit surges 19% to Rs. 27 Cr. 23-07-2015 Download
Granules India's FY15 Revenue increases 18% to Rs. 1,293 Cr.; Net Profit rises 21% to Rs. 91 Cr 27-04-2015 Download
Granules-OmniChem Private Ltd., inaugurated manufacturing facility today in Vizag 20-02-2015 Download
Granules India's Revenue increases 13% to Rs. 320 Cr.; net profit increased Rs. 24 Cr 28-01-2015 Download
Hon'ble High Court of Hyderabad approved the merger of Auctus Pharma with Granules India 13-11-2014 Download
Granules India's Revenue increases 16% to Rs. 308 Cr.; net profit surges 46% to Rs. 22 Cr 30-10-2014 Download
Granules India´s Revenue increases 36% to Rs. 311 Cr.; net profit surges 56% 24-07-2014 Download
Granules India Paracetamol API Facility completes U.S. FDA Inspection 16-06-2014 Download
Granules India Awarded Outstanding Exports (Europe & CIS) Gold Award 2012-13 by Pharmexcil 21-05-2014 Download
Demise of Founder and Chairman 15-05-2014 Download
Granules India FY14 Sales increase 43% to Rs. 1,096 Cr.; Net Profit jumps 131% to Rs. 75 Cr 24-04-2014 Download
Granules India sales increases 46% to Rs. 284 Cr.; net profit surges 275% to Rs. 22 Cr. 28-01-2014 Download
Granules India announces acquisition of Auctus Pharma and opening of a new R&D Facility 04-11-2013 Download
Granules India Revenue increases 52% to Rs. 266 Cr.; net profit surges 87% 30-10-2013 Download
Granules India Revenue increases 21% to Rs. 228 Cr.; net profit surges 134% 25-07-2013 Download
Granules India's FY13 Sales increases 17% to Rs.764cr.; Net Profit increases 9% to Rs.33cr. 25-04-2013 Download
Granules India's sales set quarterly record at Rs.195cr. 24-01-2013 Download
Granules India's revenue increases to Rs.176cr.; net profit incresed by 228%. 18-10-2012 Download
Granules India Awarded Outstanding Exports - Formulations Award 2011-12 by Pharmexcil. 28-09-2012 Download
Granules India Awarded India's Most Admired Company in Exports & India's Most Admired Company in Bulk Drugs 24-09-2012 Download
Granules India Net Revenue increases 9% due to strong ... 28-07-2012 Download
Granules India Sales increases 59% to Rs. 189 Cr. Net... 26-07-2012 Download
Granules India Announces Dividend Increase of 33% second... 02-07-2012 Download
Granules India Announces New Chief Financial Officer 26-04-2012 Download
Granules India FY12 Revenue increases 37% to Rs. 653 ... 24-04-2012 Download
Granules India Sales increases 45% to Rs. 186 Cr. Net ... 24-01-2012 Download
Granules India Net Revenue soars 37%; PBT before non-... 17-10-2011 Download
Granules India Receives U.S. FDA Approval for its Naprox... 11-10-2011 Download
Granules India Net Profit excluding exceptional items... 29-04-2011 Download
Granules India Announces New Leadership Roles 28-07-2010 Download
Granules India and Ajinomoto OmniChem to create a strate... 14-07-2010 Download
Granules India Posts Revenue of Rs.109.3 Cr. for Q1 FY11... 26-07-2010 Download
Granules India Receives U.S. FDA Approval for its Metfo... 29-04-2010 Download
Granules India Post s Record Revenue for a Quarter - Net R... 29-01-2010 Download
Granules India Posts Strong Growth During FY10 Net Revenue 05-05-2010 Download
View Archive +

Notice & Disclosures

Notice & Disclosures Download
Disclosure of Related Party Transactions for the half year ended September 30, 2019 Download
Q2 Results for the FY 2019-20 Published in Business Standard and Prajashakti on 23.10.2019 Download
Outcome of Board Meeting held on 22nd October 2019 Download
Schedule of Analyst and Investor Earnings Conference call – Q2 FY 2019-20 Download
Notice of Board meeting published on 15th October 2019 in Business Standard and Prajashakti Download
Notice of Board Meeting Scheduled on 22nd October 2019 Download
Outcome of Board Meeting held on 14th October 2019 Download
Postal Ballot Results-11.10.2019 Download
Received EIR from US FDA for Bonthapally Facility Download
Notice of Postal Ballot published on 11th September 2019 in Business Standard and Prajashakti Download
Postal Ballot Notice dated 29th August 2019 Download
28th AGM Voting results
Outcome of Board Meeting held on 29th August 2019 Download
US FDA approved the ANDA filed by GPI for Amphetamine Sulfate Tablets Download
Notice of 28th AGM published on 3rd August 2019 in Business Standard and on 4th August 2019 in Prajashakti Download
Q1 Results for the FY 2019-20 Published in Business Standard and Prajashakti on 31.07.2019 Download
Outcome of Board Meeting held on 30th July 2019 Download
Schedule of Analyst and Investor Earnings Conference call – Q1 FY 2019-20 Download
Notice of Board meeting published on 20th July 2019 in Business Standard and Prajashakti Download
Notice of Board Meeting Scheduled on 30th July 2019 Download
Disclosure of Related Party Transactions for the half year ended March 31, 2019 Download
US FDA approved the ANDA filed by GPI for Methylphenidate Hydrochloride Extended-Release capsules Download
Q4 Results for the FY 2018-19 Published in Business Standard and Prajashakti on 10.05.2019 Download
Outcome of Board Meeting held on 9th May 2019 Download
Notice of Board meeting published on 4th May 2019 in Business Standard and Prajashakti Download
Notice of Board Meeting Scheduled on 9th May 2019 Download
Schedule of Analyst and Investor Earnings Conference call – Q4 FY 2018-19 Download
Notice of Trading window closure Download
Outcome of Board Meeting held on 29th March 2019 Download
: Q3 Results for the FY 2018-19 Published in Business Standard and Prajashakti on 30.01.2019 Download
Outcome of Board Meeting held on 29th January 2019 Download
Notice of Board meeting published on 22nd January 2019 in Business Standard and Prajashakti Download
Schedule of Analyst and Investor Earnings Conference call – Q3 FY 2018-19. Download
Notice of Board Meeting Scheduled on 29th January 2019 Download
Q2 Results for the FY 2018-19 Published in Business Standard and Prajashakti on 31.10.2018 Download
Outcome of Board Meeting held on 29th October 2018 Download
US FDA completed inspection in GPI Download
Schedule of Analyst and Investors Earnings Conference call-Q2-FY2018-19 Download
Notice of Board meeting published on 23rd October 2018 in Business Standard and Prajashakti Download
Notice of Board Meeting scheduled on 29th October 2018 Download
27th AGM Voting Results Download
Notice of 27th AGM published on 15th August 2018 in Business Standard and Prajashakti Download
Q1 Results for the FY 2018-19 Published in Business Standard and Prajashakti on 25.07.2018 Download
Outcome of Board Meeting held on 23rd July 2018 Download
Notice of Board meeting published on 17th July 2018 in Business Standard and Prajashakti Download
Schedule of Analyst and Investors Earnings Conference call-Q1-FY2018-19 Download
Notice of Board Meeting scheduled on 23rd July 2018 Download
Received EIR from US FDA to Gagillapur Facility Download
Q4 Results for the FY 2017-18 Published in Business Standard and Prajashakti on 25.05.2018 Download
Outcome of Board Meeting held on 24th May 2018 Download
Notice of Board meeting published on 19th May 2018 in Business Standard and Prajashakti Download
Schedule of Analyst and Investors Earnings Conference call-Q4-FY2017-18 Download
Notice of Board Meeting scheduled on 24th May 2018 Download
Received EIR from US FDA to Jeedimetla Facility Download
Approval for Methocarbamol Download
US FDA inspection at Gagillapur and Jeedimetla facilities Download
Approval for Metformin ER Download
Received EIR from US FDA to Granules Pharmaceuticals, Inc. facility Download
Q3 Results for the FY 2017-18 Published in Business Standard and Prajashakti on 09.02.2018 Download
Outcome of Board Meeting held on 8th February 2018 Download
Notice of Board meeting published on 1st February 2018 in Business Standard and Prajashakti Download
Notice of Board Meeting scheduled on 8th February 2018 Download
Schedule of Analyst and Investors Earnings Conference call-Q3-FY2017-18 Download
Outcome of Board Meeting held on 9th November 2017 Download
Schedule of Analyst and Investors Earnings Conference call-Q2-FY2017-18 Download
Notice of Board meeting published on 2nd Nov 2017 in Business Standard and Prajashakti Download
Notice of Board Meeting scheduled on 9th November 2017 Download
26th AGM Voting Results Download
Placement Document for QIP Download
Closing of QIP Download
Notice of QIP Committee Meeting scheduled on 25.09.2017 Download
Preliminary Placement Document for Proposed QIP Download
Opening of QIP Download
Notice of 26th AGM published on 6th Sep 2017 in Business Standard and Prajashakti Download
Notice of 26th AGM Scheduled on 28th September 2017 Download
Received EIR from US FDA to Gagillapur Facility Download
Notice of record date published in Business Standard and Prajashakti on 15.08.2017 Download
Q1 Results for the FY 2017-18 Published in Business Standard and Prajashakti on 15.08.2017 Download
Schedule of Analyst and Investors Earnings Conference call-Q1-FY2017-18 Download
Outcome of Board Meeting held on 14th Aug 2017 Download
Notice of Board meeting published on 8th Aug 2017 in Business Standard and Prajashakti Download
Notice of Board Meeting Scheduled on 14th August 2017 Download
EGM voting Results-12.06.2017 Download
Notice of Extra-Ordinary General Meeting to be held on 12th June 2017 Download
e-voting Instructions for the EGM Download
Granules India’s Revenue increases 4% to Rs. 1,435 Cr.; Net Profit surges 34% to Rs. 165 Cr. Date: 11-05-2017 Download
Outcome of Board Meeting held on 11th May 2017 Download
Further notice of Board Meeting Download
Schedule of Analyst and Investors Earnings Conference call-Q4-FY2016-17 Download
Notice of Board Meeting Scheduled on 11th May 2017 Download
Outcome of 176th Board Meeting dated 28th January, 2017 Download
Schedule of Analyst and Investors Earnings Conference call-Q3-FY2016-17 Download
Notice of Board Meeting Scheduled on 28th January 2017 Download
INFARMED inspection at Gagillapur facility Download
Appointment of Director Download
BSE Approval-Part B reg. Scheme of Amalgamation Download
Granules OmniChem facility completed U.S. FDA inspection Download
High Court Order for Amalgamation of GIL Lifesciences with Granules Download
Outcome of 174th Board Meeting dated 25th October 2016 Download
Schedule of Analyst and Investors Earnings Conference call-Q2-FY2016-17 Download
Granules India’s Gagillapur facility successfully completed US FDA inspection Download
Notice of Board Meeting Scheduled on 25th October 2016 Download
Granules India Limited, received US FDA approval for Ibuprofen 200 mg Tablets Download
Schedule of Investor meet on 9th September 2016 Download
Q1 Results for the FY 2016-17 Published in Business Standard and Prajashakti on 13.08.2016 Download
25th AGM Voting Results Download
Outcome of 173rd Board Meeting Held on 11th August 2016 Download
Schedule of Analyst and Investors Earnings Conference call-Q1-FY2016-17 Download
Notice of Board Meeting Download
Date of Publication is on 14th July 2016 in Business Standard and Prajashakth Download
Intimation of Schedule of Investor Meeting Download
Intimation of Trading Window Closure Download
Compliant Report -BSE Download
BSE Observation letter from the scheme of amalgamation Download
NSE Observation letter from the scheme of amalgamation Download
Scheme of Amalgamation & Regulation 37 Documents Download
Q4 Results published in Business Standard and Prajashakti on 30.04.2016 Download
Outcome of 172nd Board Meeting Held on 28th April 2016 Download
Date of publication is on 15th April 2016 in Business standard and Prajashakti Download
Schedule of Analyst/Investors Earnings Conference call-Q4, FY 2015-16 Download
Notice of Board Meeting scheduled on April 28, 2016 Download
Intimation of Trading Window Closure Download
Intimation of Schedule of the Non Deal Road Show Download
Q3 Results published in Business Standard and Prajashakti on 29.01.2016 Download
Outcome of Board Meeting held on 28.01.2016 Download
Date of publication is on 20th January 2016 in Business standard and Prajashakti Download
Notice of Board Meeting scheduled on January 28, 2016 Download

Investor Presentation

First Quarter Second Quarter Third Quarter Fourth Quarter
FY20 Download Download
FY19 Download Download Download Download
FY18 Download Download Download Download

Shareholding Structure

First Quarter Second Quarter Third Quarter Fourth Quarter
FY20 Download Download
FY19 Download Download Download Download
FY18 Download Download Download Download

Unclaimed-Dividend

Shares Transferred to IEPF
Unpaid Dividend FY 2012-2013
Unpaid Dividend FY 2013-2014
Unpaid Dividend FY 2014-2015
Unpaid First Interim Dividend FY 2015-16
Unpaid Second Interim Dividend FY 2015-16
Unpaid Third Interim Dividend FY 2015-16
Unpaid Final Dividend FY 2015-2016
Unpaid First Interim Dividend FY 2016-17
Unpaid Second Interim Dividend FY 2016-17
Unpaid Third Interim Dividend FY 2016-17
Unpaid Final Dividend FY 2016-17
Unpaid First Interim Dividend FY 2017-18
Unpaid Second Interim Dividend FY 2017-18
Unpaid Third Interim Dividend FY 2017-18
Unpaid Final Dividend FY 2017-18
Unpaid First Interim Dividend FY 2018-19
Unpaid Second Interim Dividend FY 2018-19
Unpaid Third Interim Dividend FY 2018-19

Stock Price Information